{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:04:56Z","timestamp":1786539896846,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"10117","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","thelancet.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/s0140-6736(17)32137-2","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T19:03:32Z","timestamp":1510254212000},"page":"230-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":549,"title":["Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial"],"prefix":"10.1016","volume":"391","author":[{"given":"David L","family":"Kendler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano A F","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Greenspan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit","family":"Zikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Bagur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Malouf-Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Fahrleitner-Pammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lespessailles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Geusens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"M\u00f6ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"L\u00f3pez-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(17)32137-2_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(17)32137-2_bib2","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/S0140-6736(17)32137-2_bib3","doi-asserted-by":"crossref","first-page":"h3783","DOI":"10.1136\/bmj.h3783","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis","volume":"351","author":"Maraka","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(17)32137-2_bib4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(17)32137-2_bib5","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(17)32137-2_bib6","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/S0140-6736(17)32137-2_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1359\/jbmr.061011","article-title":"Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/S0140-6736(17)32137-2_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/S0140-6736(17)32137-2_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(17)32137-2_bib10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA Osteoporosis Study","volume":"101","author":"Dempster","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S0140-6736(17)32137-2_bib11","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/jbmr.2804","article-title":"A longitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ Trial","volume":"31","author":"Dempster","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/S0140-6736(17)32137-2_bib12","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(17)32137-2_bib13","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/S0140-6736(17)32137-2_bib14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"10.1016\/S0140-6736(17)32137-2_bib15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group","volume":"11","author":"Genant","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/S0140-6736(17)32137-2_bib16","doi-asserted-by":"crossref","first-page":"30S","DOI":"10.1016\/S0002-9343(97)90025-5","article-title":"Clinical consequences of vertebral fractures","volume":"103","author":"Ross","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/S0140-6736(17)32137-2_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1016\/S0140-6736(17)32137-2_bib18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2307\/2529876","article-title":"Random effects models for longitudinal data","volume":"38","author":"Laird","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/S0140-6736(17)32137-2_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s198-002-8331-3","article-title":"The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis","volume":"13","author":"Delmas","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/S0140-6736(17)32137-2_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMsb1006120","article-title":"The ethics of placebo in studies with fracture end points in osteoporosis","volume":"363","author":"Stein","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(17)32137-2_bib21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis. A randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(17)32137-2_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/S0140-6736(17)32137-2_bib23","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1210\/jc.2005-2602","article-title":"Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years","volume":"91","author":"Bonnick","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S0140-6736(17)32137-2_bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","article-title":"Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass","volume":"40","author":"Recker","year":"2007","journal-title":"Bone"},{"key":"10.1016\/S0140-6736(17)32137-2_bib25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2002-020400","article-title":"Risedronate prevents new vertebral fractures in postmenopausal women at high risk","volume":"88","author":"Watts","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S0140-6736(17)32137-2_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(17)32137-2_bib27","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/S0140-6736(17)32137-2_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11914-005-0023-9","article-title":"Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size","volume":"3","author":"Burr","year":"2005","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/S0140-6736(17)32137-2_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","article-title":"Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis","volume":"74","author":"Harrington","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/S0140-6736(17)32137-2_bib30","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.bone.2012.02.635","article-title":"Changes in vitamin D metabolites during teriparatide treatment","volume":"50","author":"Cosman","year":"2012","journal-title":"Bone"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673617321372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673617321372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:18:12Z","timestamp":1543450692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673617321372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":30,"journal-issue":{"issue":"10117","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0140673617321372"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(17)32137-2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732110937.793540256","asserted-by":"object"}]},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(17)32137-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(17)32167-0","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}